1. Home
  2. MAZE vs BACQ Comparison

MAZE vs BACQ Comparison

Compare MAZE & BACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAZE
  • BACQ
  • Stock Information
  • Founded
  • MAZE 2018
  • BACQ 2024
  • Country
  • MAZE United States
  • BACQ United States
  • Employees
  • MAZE N/A
  • BACQ N/A
  • Industry
  • MAZE
  • BACQ
  • Sector
  • MAZE
  • BACQ
  • Exchange
  • MAZE NYSE
  • BACQ NYSE
  • Market Cap
  • MAZE 367.0M
  • BACQ 333.2M
  • IPO Year
  • MAZE 2025
  • BACQ 2024
  • Fundamental
  • Price
  • MAZE $9.86
  • BACQ $10.16
  • Analyst Decision
  • MAZE Strong Buy
  • BACQ
  • Analyst Count
  • MAZE 3
  • BACQ 0
  • Target Price
  • MAZE $25.67
  • BACQ N/A
  • AVG Volume (30 Days)
  • MAZE 199.0K
  • BACQ 245.2K
  • Earning Date
  • MAZE 01-01-0001
  • BACQ 01-01-0001
  • Dividend Yield
  • MAZE N/A
  • BACQ N/A
  • EPS Growth
  • MAZE N/A
  • BACQ N/A
  • EPS
  • MAZE 1.25
  • BACQ N/A
  • Revenue
  • MAZE $167,500,000.00
  • BACQ N/A
  • Revenue This Year
  • MAZE N/A
  • BACQ N/A
  • Revenue Next Year
  • MAZE N/A
  • BACQ N/A
  • P/E Ratio
  • MAZE $7.86
  • BACQ $112.85
  • Revenue Growth
  • MAZE N/A
  • BACQ N/A
  • 52 Week Low
  • MAZE $6.71
  • BACQ $9.80
  • 52 Week High
  • MAZE $17.00
  • BACQ $10.14
  • Technical
  • Relative Strength Index (RSI)
  • MAZE N/A
  • BACQ N/A
  • Support Level
  • MAZE N/A
  • BACQ N/A
  • Resistance Level
  • MAZE N/A
  • BACQ N/A
  • Average True Range (ATR)
  • MAZE 0.00
  • BACQ 0.00
  • MACD
  • MAZE 0.00
  • BACQ 0.00
  • Stochastic Oscillator
  • MAZE 0.00
  • BACQ 0.00

About MAZE MAZE THERAPEUTICS INC

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

Share on Social Networks: